A recent meta-analysis cited above by Oh et al., reported that OS (HR = 2.21, 95% CI = 1.64–2.30) and cancer-specific survival (CSS) (HR = 2.63, 95% CI = 2.00–3.45) were significantly worse among BRCA2 carriers compared to noncarriers, whereas OS (HR = 0.47, 95% CI = 0.11–1.99) and CSS (HR = 1.07, 95% CI = 0.3–2.96) were not significant when comparing BRCA1 carriers and noncarriers [44]. Here, BRCA1 is linked to cancer.